Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26208940 | 0.91 | HINT1 (0.62) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL26207478 | 0.90 | HINT1 (0.58) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL26622663 | 0.89 | NT5E (0.65) | HINT1NT5ETGM2FUT5 | |
| SCHEMBL1138984 | 0.89 | HINT1 (0.75) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL26209508 | 0.88 | HINT1 (0.56) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL17198349 | 0.88 | HPGD (0.64) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL20248685 | 0.88 | HPGD (0.64) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL25711664 | 0.88 | HPGD (0.64) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL26622897 | 0.88 | HINT1 (0.61) | HINT1NT5EHPGDGSK3ARPS6KA3 | |
| SCHEMBL26622676 | 0.87 | HINT1 (0.62) | HINT1NT5EHPGDGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340009-A1 | COMPOUNDS FOR RNA CAPPING AND USES THEREOF | RNGTT, RNMT, NSUN2 | HINT1 706/4885NT5E 803/4885HPGD 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.